Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts

Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 41; no. 1; pp. 1 - 23
Main Authors Lee, Po-Ju, Sui, Yun-Hua, Liu, Tzu-Tung, Tsang, Ngan-Ming, Huang, Chen-Han, Lin, Ting-Yi, Chang, Kai-Ping, Liu, Shu-Chen
Format Journal Article
LanguageEnglish
Published London BioMed Central 20.08.2022
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.
AbstractList The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored.BACKGROUNDThe progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored.NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model.METHODSNPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model.NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature.RESULTSNPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature.EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.CONCLUSIONEBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.
Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.
Abstract Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the intercommunication between NPC and surrounding stromal cells has yet to be explored. Methods NPC biopsies were obtained for immunohistochemical (IHC) analyses. Clinical correlations between the expression of active YAP1/FAPα and the fibrotic response and between YAP1/FAPα and the density of cytotoxic CD8a+ T lymphocytes were determined. Survival times based on IHC scores were compared between groups using Kaplan-Meier survival and log-rank tests. Independent prognostic factors for metastasis/recurrence-free survival and overall survival were identified using univariate and multivariate Cox regression models. Fibroblasts were isolated from human nasopharyngeal biopsies. Exosomes were purified from culture supernatants of EBV+-positive NPC cells. The effects of EBV product-containing exosomes on fibroblast activation, fibrotic response, tumor growth, immune response, and correlations between the expression of featured genes were investigated using gel contraction assays, ELISAs, EdU incorporation assays, real-time impedance assays, RNA sequencing, immunostaining, 3D cancer spheroid coculture systems, and an NPC xenograft model. Results NPC patients who developed metastasis had significantly higher levels of active YAP1 and FAPα in their tumor stroma, which was further correlated with tumor fibrosis and poorer metastasis-free survival. Exosomes released from EBV+-NPC cells contained abundant FAPα protein and EBV-encoded latent membrane protein 1. Viral product-containing exosomes markedly enhanced the fibrotic response and tumor growth in a mouse xenograft model. IHC analyses of human NPC and NPC xenografts revealed positive correlations between levels of active YAP1 and FAPα, YAP1 and the fibrotic response, and FAPα and the fibrotic response. Mechanistic studies showed that treatment of fibroblasts with viral product-containing exosomes promoted the characteristics of cancer-associated fibroblasts by stimulating YAP1 signaling and the production of the immunosuppressive cytokines IL8, CCL2, and IL6. Inhibition of YAP1 activation markedly reversed these exosome-mediated protumoral effects, resulting in reduced contractility, inactivation of YAP1 signaling, and decreased production of immunosuppressive cytokines in fibroblasts. Furthermore, fibroblasts stimulated with these viral product-containing exosomes promoted NPC resistance to T cell-mediated cytotoxicity within tumor spheroids. In NPC tissues, a significant negative correlation was found between YAP1/FAPα and the density of CD8a+ T lymphocytes with a granzyme B signature. Conclusion EBV orchestrates interactions with the host and surrounding stroma by stimulating the functions of YAP1 and FAPα in fibroblasts through exosome cargos to create a more immunosuppressive, proinvasive microenvironment.
ArticleNumber 254
Author Tsang, Ngan-Ming
Chang, Kai-Ping
Lee, Po-Ju
Sui, Yun-Hua
Huang, Chen-Han
Liu, Shu-Chen
Liu, Tzu-Tung
Lin, Ting-Yi
Author_xml – sequence: 1
  givenname: Po-Ju
  surname: Lee
  fullname: Lee, Po-Ju
– sequence: 2
  givenname: Yun-Hua
  surname: Sui
  fullname: Sui, Yun-Hua
– sequence: 3
  givenname: Tzu-Tung
  surname: Liu
  fullname: Liu, Tzu-Tung
– sequence: 4
  givenname: Ngan-Ming
  surname: Tsang
  fullname: Tsang, Ngan-Ming
– sequence: 5
  givenname: Chen-Han
  surname: Huang
  fullname: Huang, Chen-Han
– sequence: 6
  givenname: Ting-Yi
  surname: Lin
  fullname: Lin, Ting-Yi
– sequence: 7
  givenname: Kai-Ping
  surname: Chang
  fullname: Chang, Kai-Ping
– sequence: 8
  givenname: Shu-Chen
  surname: Liu
  fullname: Liu, Shu-Chen
BookMark eNp9Us1u1DAQtlARbRdegFMkLlxC7fgn8QVpqVqoVIke4MDJcmwn61ViB9tZldfhDXgRnglnUyTaAwfL1sz3feOZ-c7BifPOAPAawXcINewiIgwJK2FV5UMoK-kzcIbq_OCcsZN_3qfgPMY9hAxxxF-AU0x5wzDjZ-Dn1RSTsa78IEMoDjbIoZiC17NKpfIuSeus6wtz76MfTVxyo0-m6GwbfLSxkE4XTkY_7WT44XqT-UoGZZ0f5YLug4nRelekXfBzvyukSvYg0xLyXfFte4currd3v38V0fZODks161b9dpAxxZfgeSeHaF493Bvw9frqy-Wn8vbzx5vL7W2pSI1TyQypatVKRnnbIGK04rBrGalhzVAFYW0gpqTjRmvaorZpJOWG0w4SaThkEm_AzaqrvdyLKdgxdyS8tOIY8KEXMiSrBiMQww00GmleY1JxzTXRNcEQYgSpPmq9X7WmuR3zV4xLebKPRB9nnN2J3h8Ex7zCFcoCbx8Egv8-m5jEaKMywyCd8XMUVQ1Jw2qU0Rvw5gl07-eQR7mgEM2CDNKMalaUynuLwXRC2XRcQ65vB4GgWEwlVlOJbCpxNJVYqNUT6t8-_kP6A-9Y1Ac
CitedBy_id crossref_primary_10_1007_s13402_023_00888_5
crossref_primary_10_2967_jnumed_123_266183
crossref_primary_10_1093_nargab_lqad106
crossref_primary_10_1186_s12575_024_00245_2
crossref_primary_10_1093_pcmedi_pbae018
crossref_primary_10_1016_j_canlet_2023_216225
crossref_primary_10_1016_j_heliyon_2024_e30808
crossref_primary_10_1186_s12943_024_01932_0
crossref_primary_10_1186_s12935_022_02784_8
crossref_primary_10_25259_Cytojournal_149_2024
crossref_primary_10_1016_j_intimp_2024_114011
crossref_primary_10_3390_medicina59010002
crossref_primary_10_1016_j_gendis_2023_101117
crossref_primary_10_1016_j_jdermsci_2023_12_004
crossref_primary_10_3389_fimmu_2024_1377722
crossref_primary_10_1016_j_canlet_2024_217244
crossref_primary_10_1186_s12957_024_03441_2
crossref_primary_10_3390_cancers16050919
crossref_primary_10_3389_fimmu_2025_1560897
crossref_primary_10_1038_s41389_025_00549_2
crossref_primary_10_1016_j_virusres_2024_199352
crossref_primary_10_1186_s12967_024_06064_z
Cites_doi 10.1084/jem.20140692
10.1016/S1040-8428(02)00115-4
10.1186/1471-2105-14-7
10.1038/nrc1452
10.1038/nrm.2017.87
10.1182/blood-2008-02-142596
10.1093/emboj/19.24.6778
10.1038/s41467-018-07660-6
10.1038/ncb3336
10.1038/s41422-020-0374-x
10.3390/ijms19113674
10.1172/JCI88759
10.1172/JCI63428
10.1016/S1097-2765(02)00776-1
10.3390/pathogens7020040
10.1074/mcp.M900381-MCP200
10.1073/pnas.1220998110
10.1002/ijc.22334
10.1158/0008-5472.CAN-10-1722
10.1038/ncomms15321
10.1006/scbi.2001.0412
10.1038/nrc3876
10.1002/mc.23150
10.1038/ncb2303
10.1016/j.semcancer.2008.10.004
10.1016/j.intimp.2009.01.015
10.1073/pnas.0506580102
10.1016/j.semcancer.2008.10.002
10.1101/gad.173435.111
10.1016/j.semcancer.2013.12.009
10.1158/1078-0432.CCR-06-2945
10.1016/j.virol.2010.06.037
10.1038/onc.2008.250
10.1016/j.ccr.2014.03.007
10.3390/cancers10040106
10.1111/cas.13473
10.2147/CMAR.S167071
10.1038/ncb1725
10.1016/j.jhep.2015.04.011
10.1016/j.xinn.2021.100141
10.1073/pnas.1014194107
10.1158/1535-7163.MCT-11-0340
10.1016/j.canlet.2013.05.012
10.1038/onc.2014.66
ContentType Journal Article
Copyright 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13046-022-02456-5
DatabaseName CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central (New)
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 23
ExternalDocumentID oai_doaj_org_article_16380ed1d973429d9d4d743003105d6a
PMC9392321
10_1186_s13046_022_02456_5
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c473t-6e427cba659b814edc90fb64707612007e0354f9edd5b1b88a59e95f04ae906a3
IEDL.DBID M48
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:25:17 EDT 2025
Thu Aug 21 17:40:49 EDT 2025
Fri Jul 11 04:08:17 EDT 2025
Fri Jul 25 08:08:47 EDT 2025
Thu Apr 24 22:57:23 EDT 2025
Tue Jul 01 02:26:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c473t-6e427cba659b814edc90fb64707612007e0354f9edd5b1b88a59e95f04ae906a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/16380ed1d973429d9d4d743003105d6a
PMID 35986369
PQID 2715392605
PQPubID 105475
PageCount 23
ParticipantIDs doaj_primary_oai_doaj_org_article_16380ed1d973429d9d4d743003105d6a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9392321
proquest_miscellaneous_2704867192
proquest_journals_2715392605
crossref_citationtrail_10_1186_s13046_022_02456_5
crossref_primary_10_1186_s13046_022_02456_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-20
PublicationDateYYYYMMDD 2022-08-20
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-20
  day: 20
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationYear 2022
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References P Kucharzewska (2456_CR7) 2013; 110
T Ogino (2456_CR18) 2007; 120
A Elosegui-Artola (2456_CR40) 2016; 18
S Hänzelmann (2456_CR35) 2013; 14
I Mannaerts (2456_CR33) 2015; 63
JM Middeldorp (2456_CR13) 2008; 18
T Moroishi (2456_CR47) 2015; 15
2456_CR26
F Liu (2456_CR32) 2015; 308
YP Chen (2456_CR48) 2020; 30
H Kanegane (2456_CR17) 2002; 44
S Basu (2456_CR30) 2003; 11
2456_CR44
YM Chang (2456_CR45) 2008; 27
F Kanai (2456_CR31) 2000; 19
K Al-Nedawi (2456_CR6) 2008; 10
2456_CR27
B Zhao (2456_CR41) 2012; 26
HC Lai (2456_CR15) 2010; 405
K Houali (2456_CR24) 2007; 13
D Ohlund (2456_CR2) 2014; 211
G Nardone (2456_CR39) 2017; 8
Y Yu (2456_CR3) 2018; 10
S Pai (2456_CR14) 2001; 11
SC Liu (2456_CR19) 2013; 123
S Wang (2456_CR5) 2014; 2014
J Klibi (2456_CR25) 2009; 113
DG Meckes Jr (2456_CR21) 2010; 107
J Li (2456_CR16) 2009; 9
O De Wever (2456_CR1) 2014; 25
C Munz (2456_CR12) 2008; 18
B Zhao (2456_CR29) 2011; 13
2456_CR36
H Zheng (2456_CR20) 2007; 4
T Yoshizaki (2456_CR28) 2018; 109
YH Zhu (2456_CR4) 2020; 59
T Panciera (2456_CR42) 2017; 18
V Ramjee (2456_CR43) 2017; 127
WN Brennen (2456_CR46) 2012; 11
W Zhou (2456_CR9) 2014; 25
LS Young (2456_CR11) 2004; 4
M Aga (2456_CR23) 2014; 33
2456_CR38
CT Lin (2456_CR34) 1993; 68
A Subramanian (2456_CR37) 2005; 102
JE Park (2456_CR8) 2010; 9
J Webber (2456_CR10) 2010; 70
A Canitano (2456_CR22) 2013; 337
References_xml – volume: 4
  start-page: 185
  year: 2007
  ident: 2456_CR20
  publication-title: Cell Mol Immunol
– volume: 211
  start-page: 1503
  year: 2014
  ident: 2456_CR2
  publication-title: J Exp Med
  doi: 10.1084/jem.20140692
– volume: 44
  start-page: 239
  year: 2002
  ident: 2456_CR17
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/S1040-8428(02)00115-4
– volume: 14
  start-page: 7
  year: 2013
  ident: 2456_CR35
  publication-title: BMC Bioinformatics
  doi: 10.1186/1471-2105-14-7
– volume: 4
  start-page: 757
  year: 2004
  ident: 2456_CR11
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1452
– volume: 18
  start-page: 758
  year: 2017
  ident: 2456_CR42
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2017.87
– volume: 113
  start-page: 1957
  year: 2009
  ident: 2456_CR25
  publication-title: Blood
  doi: 10.1182/blood-2008-02-142596
– volume: 19
  start-page: 6778
  year: 2000
  ident: 2456_CR31
  publication-title: EMBO J
  doi: 10.1093/emboj/19.24.6778
– ident: 2456_CR38
  doi: 10.1038/s41467-018-07660-6
– volume: 18
  start-page: 540
  year: 2016
  ident: 2456_CR40
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3336
– volume: 30
  start-page: 1024
  year: 2020
  ident: 2456_CR48
  publication-title: Cell Res
  doi: 10.1038/s41422-020-0374-x
– ident: 2456_CR44
  doi: 10.3390/ijms19113674
– volume: 127
  start-page: 899
  year: 2017
  ident: 2456_CR43
  publication-title: J Clin Invest
  doi: 10.1172/JCI88759
– volume: 123
  start-page: 5269
  year: 2013
  ident: 2456_CR19
  publication-title: J Clin Invest
  doi: 10.1172/JCI63428
– volume: 11
  start-page: 11
  year: 2003
  ident: 2456_CR30
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(02)00776-1
– ident: 2456_CR27
  doi: 10.3390/pathogens7020040
– volume: 9
  start-page: 1085
  year: 2010
  ident: 2456_CR8
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.M900381-MCP200
– volume: 110
  start-page: 7312
  year: 2013
  ident: 2456_CR7
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1220998110
– volume: 308
  start-page: L344
  year: 2015
  ident: 2456_CR32
  publication-title: Am J Phys Lung Cell Mol Phys
– volume: 120
  start-page: 2401
  year: 2007
  ident: 2456_CR18
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22334
– volume: 70
  start-page: 9621
  year: 2010
  ident: 2456_CR10
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1722
– volume: 8
  start-page: 15321
  year: 2017
  ident: 2456_CR39
  publication-title: Nat Commun
  doi: 10.1038/ncomms15321
– volume: 2014
  start-page: 507353
  year: 2014
  ident: 2456_CR5
  publication-title: Biomed Res Int
– volume: 11
  start-page: 455
  year: 2001
  ident: 2456_CR14
  publication-title: Semin Cancer Biol
  doi: 10.1006/scbi.2001.0412
– volume: 15
  start-page: 73
  year: 2015
  ident: 2456_CR47
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3876
– volume: 59
  start-page: 265
  year: 2020
  ident: 2456_CR4
  publication-title: Mol Carcinog
  doi: 10.1002/mc.23150
– volume: 13
  start-page: 877
  year: 2011
  ident: 2456_CR29
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2303
– volume: 68
  start-page: 716
  year: 1993
  ident: 2456_CR34
  publication-title: Lab Investig
– volume: 18
  start-page: 388
  year: 2008
  ident: 2456_CR13
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2008.10.004
– volume: 9
  start-page: 590
  year: 2009
  ident: 2456_CR16
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2009.01.015
– volume: 102
  start-page: 15545
  year: 2005
  ident: 2456_CR37
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0506580102
– volume: 18
  start-page: 381
  year: 2008
  ident: 2456_CR12
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2008.10.002
– volume: 26
  start-page: 54
  year: 2012
  ident: 2456_CR41
  publication-title: Genes Dev
  doi: 10.1101/gad.173435.111
– volume: 25
  start-page: 33
  year: 2014
  ident: 2456_CR1
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2013.12.009
– volume: 13
  start-page: 4993
  year: 2007
  ident: 2456_CR24
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2945
– volume: 405
  start-page: 464
  year: 2010
  ident: 2456_CR15
  publication-title: Virology
  doi: 10.1016/j.virol.2010.06.037
– volume: 27
  start-page: 6365
  year: 2008
  ident: 2456_CR45
  publication-title: Oncogene
  doi: 10.1038/onc.2008.250
– volume: 25
  start-page: 501
  year: 2014
  ident: 2456_CR9
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.03.007
– ident: 2456_CR26
  doi: 10.3390/cancers10040106
– volume: 109
  start-page: 272
  year: 2018
  ident: 2456_CR28
  publication-title: Cancer Sci
  doi: 10.1111/cas.13473
– volume: 10
  start-page: 1935
  year: 2018
  ident: 2456_CR3
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S167071
– volume: 10
  start-page: 619
  year: 2008
  ident: 2456_CR6
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1725
– volume: 63
  start-page: 679
  year: 2015
  ident: 2456_CR33
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.04.011
– ident: 2456_CR36
  doi: 10.1016/j.xinn.2021.100141
– volume: 107
  start-page: 20370
  year: 2010
  ident: 2456_CR21
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1014194107
– volume: 11
  start-page: 257
  year: 2012
  ident: 2456_CR46
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0340
– volume: 337
  start-page: 193
  year: 2013
  ident: 2456_CR22
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2013.05.012
– volume: 33
  start-page: 4613
  year: 2014
  ident: 2456_CR23
  publication-title: Oncogene
  doi: 10.1038/onc.2014.66
SSID ssj0061919
Score 2.447226
Snippet Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the...
The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in the...
Abstract Background The progression of nasopharyngeal carcinoma (NPC) is profoundly affected by Epstein-Barr virus (EBV) infection. However, the role of EBV in...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Biopsy
Cancer
Collagen
Cytokines
EBV
Epstein-Barr virus
Exosome
Experiments
Fibroblast
Fibroblasts
Laboratory animals
Metastasis
MicroRNAs
Nasopharyngeal carcinoma
NPC
Proteins
Throat cancer
Vascular endothelial growth factor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4lcECjISN2RtnNhOfNyiriqkoh6oVE6WHTuwUuusNlsJXoc34EV4Jmbs7Kq5wIVr7FiJZ-z5xjP-hpB3GMzzQZfMw_7IkBGcaV11DGxPKftWe5vuVp1_UmeX4uOVvLpT6gtzwjI9cJ64BeKFMnjudVPD3um1Fx6sXqK0lF4laAQ2b-9M5T0YvAKu91dkWrUYOQYAGWauY6hRMTkzQ4mtfwYx5wmSdyzO6hF5OEFFusyf-JjcC_EJuX8-BcOfkp-nmxFrVbITu91STNa9pptM4MowAz3XfqDh-zAON2HENpBLoD14yMO4HqmNnkaLdQzs9kf8CpCRdlhaKA43lqbErUzaQadiPhQvQeQjXDr09Mvygi9Wy4vfvyhmgVi82E7XMY_vAJXvxmfkcnX6-cMZm0ousE409Y6pIKqmc1ZJ7VouYAZ02TslGjzuwGPNUNZS9Dp4Lx13bWulDlr2pbAgcGXr5-QoDjG8IJTXXtWVtpULjehLB0CothLpZ_pO-yoUhO8lYLqJjxzLYlyb5Je0ymSpGZCaSVIzsiDvD-9sMhvHX3ufoGAPPZFJOz0A_TKTfpl_6VdBjvdqYablPZqqAUOh0RUsyNtDMyxMjLbYGIZb7JPYDAFBF6SZqdPsg-Ytcf0tUXxrGL2u-Mv_8QevyIMqaT5uicfkaLe9Da8BSe3cm7Ro_gAShhzC
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgLKn8iUJCRuCFr82cnPlVb1FWFVNQDlZaT5cROWam1l2Qr0dfpG_AifabOON6FXHpde7OrzIz9eWb8fYR8xmKesTJlBtZHhozgTMq8ZbD3pLyrpdHhbtXpd3FyXn5b8mVMuA2xrXK7JoaF2vgWc-SzvILYlIi-D9e_GapGYXU1Smg8Jk-Qugxbuqrl7sAFZ4Mg7AE7pGCI67eXZmoxGzIsCTLsZcfio2B8sjEF_v4J6Jy2TP63By32yfMIHul8tPYL8si6l-TpaSyPvyK3x-sB1SvZke57iu27l3Q9Uroy7Ekf1SCo_eMHf2UHHANLWdrBmdkPq4FqZ6jTqGyg-xt3ASCStig25PyVpqGVa6TxoFHeh-K1iDGpS31Hf87Pstlifnb3l2JfiMar7nTlxuc3gNM3w2tyvjj-8fWERREG1pZVsWHClnnVNlpw2dRZCW9Apl0jygoTIJjotGnBy05aY3iTNXWtubSSd2mpwQWELt6QPeedfUtoVhhR5FLnja3KLm0AGhWaIyFN10qT24RkWwuoNjKUo1DGpQonlVqo0WoKrKaC1RRPyJfdd9YjP8eDs4_QsLuZyK0dPvD9hYqhqhChptZkRlYF7NZGmtIAzgokqtwInZCDrVuoGPCD-ueeCfm0G4ZQxfqLdtZf45zAbwiYOiHVxJ0mf2g64la_Aum3hKcXefbu4R9_T57lwadx-Tsge5v-2n4A1LRpPobQuAfz2Reg
  priority: 102
  providerName: ProQuest
Title Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts
URI https://www.proquest.com/docview/2715392605
https://www.proquest.com/docview/2704867192
https://pubmed.ncbi.nlm.nih.gov/PMC9392321
https://doaj.org/article/16380ed1d973429d9d4d743003105d6a
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3bitswEBV7gdKX0it1uw0q9K2o65sk66GUpCQshSxhaSDti5EteTeQtVM7C7u_0z_oj_SbOiPboYal9CUPkSKCZ8ZzpBmdQ8g7LOYZq3xm4P3IkBGcKRXmDHKPz4tEGe3uVs3Pxdky_rLiqwPSyx11D7C5d2uHelLLevPh9sfdJwj4jy7gE3HaBFjeY9iXjoVEwfghOYbMJDFQ5_G-qgB7BSf0ARlTMMT5_SWae9cYJCrH5z8AocMWyr9y0uwxedSBSTpurf-EHNjyKXkw78rlz8jP6bZBNUs20XVNsZ13Q7ctxSvDHvVWHYLa26qprm2DY2A5SwvYQ1fNuqG6NLTUqHSg67vyEkAlzVF8qKyuNXWtXS2tB-3kfihek2gPeWlV0G_jRXA6Gy9-_6LYJ6Lx6jtdl-36GeD2XfOcLGfTr5_PWCfKwPJYRjsmbBzKPNOCqywJYngCyi8yEUs8EMGDT-tHPC6UNYZnQZYkmiureOHHGlxC6OgFOSqr0r4kNIiMiEKlw8zKuPAzgEqR5khQU-TKhNYjQW-BNO8Yy1E4Y5O6nUsi0tZqKVgtdVZLuUfe73-zbfk6_jl7gobdz0SubfdFVV-mXeimiFh9awKjZATZ2ygTG8BdjlSVG6E9ctK7Rdr7bxpKSCUKN4seebsfhtDFeowubXWDcxzfIWBsj8iBOw3-0HCkXF85EnAFq0dh8Oo_Vn9NHobOsfGdeEKOdvWNfQNQapeNyKFcyRE5nkzPFxcjdyAxcjEDnxeT738AWLMhWg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviL-iMMBI8ISs5p-d-AGhFlp1bK0qtEnjyTixMyptSWk6wb4OHwCJL8Jn4s5JCnnZ215rx2l05_Od7-73I-QVJvOMlR4zYB8ZIoIzKYOMwdnj8TyRRrveqtlcTI-jjyf8ZIf8anthsKyytYnOUJsywzvyQRDD3pTofb9bfWPIGoXZ1ZZCo1aLA3v5HUK26u3-B5Dv6yCYjI_eT1nDKsCyKA43TNgoiLNUCy7TxI-syaSXpyKKMaLHmzvrhTzKpTWGp36aJJpLK3nuRRq-SegQ1r1BdqMQQpke2R2N54tPre2HaMRRicCZLBhGEm2bTiIGlY9JSIbV85juFIx3jkLHGNBxc7tFmv-depO75E7jrtJhrV_3yI4t7pObsyYh_4D8HK8q5MtkI71eUywYPqOrGkSWYRV8zT9B7Y-yKs9thWOgG5bmEKWX1bKiujC00MiloNeXxSm4rTRDeqOiPNfUFY_VwCG0IRSi2IhRXyPTMqefhwt_MBku_vymWImisbmeLot6_RQig031kBxfi4AekV5RFvYxoX5oRBhIHaQ2jnIvBWcs1BwhcPJMmsD2id9KQGUNJjpSc5wpFxslQtVSUyA15aSmeJ-82T6zqhFBrpw9QsFuZyKat_uhXJ-qxjgo9Ik9a3wj4xD8AyNNZMCzc7Ct3AjdJ3utWqjGxFTq34bok5fbYTAOmPHRhS0vcI5DVAQvvk_ijjp1_lB3pFh-dTDjElYPA__J1S9_QW5Nj2aH6nB_fvCU3A6cfqPx3SO9zfrCPgOfbZM-bzYKJV-ue2_-BbaHVV0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epstein-Barr+viral+product-containing+exosomes+promote+fibrosis+and+nasopharyngeal+carcinoma+progression+through+activation+of+YAP1%2FFAP%CE%B1+signaling+in+fibroblasts&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Lee%2C+Po-Ju&rft.au=Sui%2C+Yun-Hua&rft.au=Liu%2C+Tzu-Tung&rft.au=Tsang%2C+Ngan-Ming&rft.date=2022-08-20&rft.issn=1756-9966&rft.eissn=1756-9966&rft.volume=41&rft.issue=1&rft.spage=254&rft_id=info:doi/10.1186%2Fs13046-022-02456-5&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon